Related Experiment Video
Updated: Jun 13, 2026

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
Published on: May 3, 2017
Aging-Dependent Loss of Connectivity in Alzheimer's Model Mice with Rescue by mGluR5 Modulator
Abstract:
Amyloid accumulation in Alzheimer's disease (AD) is associated with synaptic damage and altered connectivity in brain networks. While measures of amyloid accumulation and biochemical changes in mouse models have utility for translational studies of certain therapeutics, preclinical analysis of altered brain connectivity using clinically relevant fMRI measures has not been well developed for agents intended to improve neural networks. Here, we conduct a longitudinal study in a double knock-in mouse model for AD ( App NL-G-F /hMapt ), monitoring brain connectivity by means of resting-state fMRI. While the 4-month-old AD mice are indistinguishable from wild-type controls (WT), decreased connectivity in the default-mode network is significant for the AD mice relative to WT mice by 6 months of age and is pronounced by 9 months of age. In a second cohort of 20-month-old mice with persistent functional connectivity deficits for AD relative to WT, we assess the impact of two-months of oral treatment with a silent allosteric modulator of mGluR5 (BMS-984923) known to rescue synaptic density. Functional connectivity deficits in the aged AD mice are reversed by the mGluR5-directed treatment. The longitudinal application of fMRI has enabled us to define the preclinical time trajectory of AD-related changes in functional connectivity, and to demonstrate a translatable metric for monitoring disease emergence, progression, and response to synapse-rescuing treatment.
Insights
Alzheimer's disease (AD) alters brain connectivity, detectable by fMRI. A novel treatment targeting mGluR5 reversed these functional connectivity deficits in aged AD mice.
Area of Science:
- Neuroscience
- Biomedical Engineering
- Pharmacology
Background:
- Alzheimer's disease (AD) is characterized by amyloid accumulation, synaptic damage, and altered brain network connectivity.
- Preclinical assessment of brain connectivity using functional magnetic resonance imaging (fMRI) is crucial for developing therapeutics targeting neural networks.
Approach:
- A longitudinal study utilized resting-state fMRI to monitor brain connectivity in a double knock-in mouse model for AD (App).
- The study assessed the impact of a silent allosteric modulator of mGluR5 (BMS-984923) on functional connectivity deficits in aged AD mice.
Key Points:
- Decreased default-mode network connectivity emerged in AD mice by 6 months of age and was pronounced by 9 months.
- Two months of oral BMS-984923 treatment reversed functional connectivity deficits in aged AD mice.
- fMRI provided a translatable metric for monitoring AD emergence, progression, and treatment response.
Conclusions:
- Resting-state fMRI can track the preclinical trajectory of AD-related functional connectivity changes.
- mGluR5 modulation with BMS-984923 shows potential for reversing synaptic and connectivity deficits in Alzheimer's disease.
More Related Videos
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
08:27Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
Published on: March 11, 2020
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer Disease ll: Pathophysiology